CF
SLNO

Cantor Fitzgerald’s Soleno Therapeutics SLNO Stock Holding History

Cantor Fitzgerald’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$1.07M – 524
2025
Q1 		$1.07M Buy
+15,000
New +$730K 0.02% 111

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Cantor Fitzgerald's SLNO Position: Q1 2026 in Review

Cantor Fitzgerald opened a new position in Soleno Therapeutics (SLNO) in Q1 2026: 30,000 shares worth $1M. The stake represents 0.01% of the portfolio and ranks #177 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in SLNO as recently as Q1 2025.

Cantor Fitzgerald first reported a position in SLNO in Q4 2024 and has held it in 3 quarters since. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Cantor Fitzgerald held 30,000 shares of Soleno Therapeutics worth $1M as of Q1 2026.
  • Soleno Therapeutics was a new Cantor Fitzgerald position in Q1 2026.
  • Soleno Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #177 holding.
  • Cantor Fitzgerald first reported a position in Soleno Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.